Literature DB >> 21932096

Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease.

Andreas Fellgiebel1, Dominik O Wolf, Edwin Kolodny, Matthias J Müller.   

Abstract

Cerebral micro- and macro-vasculopathy have been described in Fabry disease (FD). Neuronal globotriaosylceramide accumulation in selective cortical and brain stem areas including the hippocampus has been reported by autopsy studies in FD, but clinical surrogates as well as the clinical relevance of these findings have not been investigated so far. We measured the hippocampus volumes in a group of clinically affected patients with FD and correlated the findings with the cognitive performance of the patients. Hippocampal volumes were determined manually on T1-weighted MR-images of 25 FD patients (age 36.5 ± 11.0 years) and 20 age-matched controls. Additionally, individual white matter (WM) and gray matter (GM) volumes were measured using brain segmentation analyses. After controlling for age, white matter lesion (WML) volume, and WM/GM-volumes hippocampal volumes were significantly decreased in FD. These findings were substantially more pronounced in a subgroup of men with FD. WM and WM/GM volumes, and memory function did not significantly differ between patients and controls. In patients with FD hippocampal volumes were neither significantly correlated to WML volume nor to WM or WM/GM volumes. Hippocampus atrophy was not driven by the WML or other brain tissue atrophy and seems to correlate with the neuronal involvement in FD. In this young to middle-aged Fabry cohort the hippocampus degeneration was functionally compensated without memory impairment. Longitudinal studies are needed to determine whether this degenerative component in FD will progress and, in concert with the individual WML-load, predict subsequent cognitive decline.

Entities:  

Mesh:

Year:  2011        PMID: 21932096     DOI: 10.1007/s10545-011-9390-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  Evidence of a smaller left hippocampus and left temporal horn in both patients with first episode schizophrenia and normal control subjects.

Authors:  K Niemann; A Hammers; V A Coenen; A Thron; J Klosterkötter
Journal:  Psychiatry Res       Date:  2000-08-28       Impact factor: 3.222

2.  White matter lesion severity in male and female patients with Fabry disease.

Authors:  A Fellgiebel; M J Müller; M Mazanek; K Baron; M Beck; P Stoeter
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

3.  CNS manifestations of Fabry's disease.

Authors:  Andreas Fellgiebel; Matthias J Müller; Lionel Ginsberg
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

4.  Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation.

Authors:  E M Kaye; E H Kolodny; E L Logigian; M D Ullman
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

Review 5.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

6.  Brain atrophy and cerebral small vessel disease: a prospective follow-up study.

Authors:  Arani Nitkunan; Silvia Lanfranconi; Rebecca A Charlton; Thomas R Barrick; Hugh S Markus
Journal:  Stroke       Date:  2010-12-09       Impact factor: 7.914

7.  Neuropsychiatric symptoms and brain structural alterations in Fabry disease.

Authors:  I Schermuly; M J Müller; K-M Müller; J Albrecht; I Keller; I Yakushev; M Beck; A Fellgiebel
Journal:  Eur J Neurol       Date:  2011-02       Impact factor: 6.089

8.  An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia.

Authors:  Riki Okeda; Masahiro Nisihara
Journal:  Neuropathology       Date:  2008-04-11       Impact factor: 1.906

9.  Voxel based analyses of diffusion tensor imaging in Fabry disease.

Authors:  J Albrecht; P R Dellani; M J Müller; I Schermuly; M Beck; P Stoeter; A Gerhard; A Fellgiebel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-20       Impact factor: 10.154

10.  The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

Authors:  C Whybra; C Kampmann; F Krummenauer; M Ries; E Mengel; E Miebach; F Baehner; K Kim; M Bajbouj; A Schwarting; A Gal; M Beck
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

View more
  12 in total

1.  Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessments.

Authors:  Virginia G Wadley; Leslie A McClure; David G Warnock; Caroline L Lassen-Greene; Robert J Hopkin; Dawn A Laney; Virginia M Clarke; Manjula Kurella Tamura; George Howard; Katherine Sims
Journal:  JIMD Rep       Date:  2015-01-08

2.  Diffusion tensor imaging and brain volumetry in Fabry disease patients.

Authors:  Teemu Paavilainen; Virva Lepomäki; Jani Saunavaara; Ronald Borra; Pirjo Nuutila; Ilkka Kantola; Riitta Parkkola
Journal:  Neuroradiology       Date:  2013-01-05       Impact factor: 2.804

3.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

Review 4.  Cognitive dysfunction and depression in Fabry disease: a systematic review.

Authors:  Fay E Bolsover; Elaine Murphy; Lisa Cipolotti; David J Werring; Robin H Lachmann
Journal:  J Inherit Metab Dis       Date:  2013-08-16       Impact factor: 4.982

Review 5.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

Review 6.  Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now.

Authors:  Idalina Beirão; Ana Cabrita; Márcia Torres; Fernando Silva; Patrício Aguiar; Francisco Laranjeira; Ana Marta Gomes
Journal:  Diseases       Date:  2017-06-11

Review 7.  Neuroimaging in Fabry disease: current knowledge and future directions.

Authors:  Sirio Cocozza; Camilla Russo; Giuseppe Pontillo; Antonio Pisani; Arturo Brunetti
Journal:  Insights Imaging       Date:  2018-11-02

8.  Reduced Intracranial Volume in Fabry Disease: Evidence of Abnormal Neurodevelopment?

Authors:  Giuseppe Pontillo; Sirio Cocozza; Arturo Brunetti; Vincenzo Brescia Morra; Eleonora Riccio; Camilla Russo; Francesco Saccà; Enrico Tedeschi; Antonio Pisani; Mario Quarantelli
Journal:  Front Neurol       Date:  2018-08-17       Impact factor: 4.003

9.  Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease.

Authors:  Irene M Lelieveld; Anna Böttcher; Julia B Hennermann; Michael Beck; Andreas Fellgiebel
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

10.  Altered Gene Expression in Prefrontal Cortex of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Miodrag Mitrić; Michiel Langeslag; Michaela Kress
Journal:  Front Mol Neurosci       Date:  2018-06-25       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.